Johnson & Johnson's NYSE: JNJ stock chart is sending a clear signal that contrasts sharply with the persistent hum of repetitive negative headlines. While news cycles continue to circle long-running legal battles, the company's market performance paints a picture of investor confidence, with its stock climbing over 23% year-to-date.
Dividend stocks aren't all created equal. Some decrease their payouts, or suspend them altogether, when they face headwinds.
It's a move to boost its domestic production as President Donald Trump threatens to slap devastating tariffs on pharmaceutical imports.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Johnson & Johnson said on Thursday it would invest $2 billion in North Carolina as it aims to expand its U.S. manufacturing presence amid looming drug import duties proposed by President Donald Trump's administration.
J&J battles Stelara losses, talc lawsuits, tariffs and China headwinds while banking on growth plans and new launches to stay resilient.
For long-term investors, dividend-paying companies remain a key factor as they provide both income and stability.
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
JNJ offers resilience and income, while Apple fuels long-term growth???ideal picks for a stress-free retirement portfolio.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.